Stemline Therapeutics Inc (NASDAQ:STML) saw unusually-strong trading volume on Friday . Approximately 2,407,398 shares changed hands during mid-day trading, an increase of 217% from the previous session’s volume of 760,106 shares.The stock last traded at $13.62 and had previously closed at $13.47.
A number of research analysts have recently commented on STML shares. Roth Capital set a $33.00 price objective on Stemline Therapeutics and gave the company a “buy” rating in a report on Sunday, December 2nd. HC Wainwright set a $38.00 price objective on Stemline Therapeutics and gave the company a “buy” rating in a report on Friday, December 7th. ValuEngine upgraded Stemline Therapeutics from a “hold” rating to a “buy” rating in a report on Friday, November 23rd. Piper Jaffray Companies set a $20.00 price objective on Stemline Therapeutics and gave the company a “buy” rating in a report on Friday, December 21st. Finally, BidaskClub upgraded Stemline Therapeutics from a “sell” rating to a “hold” rating in a report on Friday, November 23rd. Three investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. The stock has a consensus rating of “Buy” and an average target price of $25.40.
The company has a market capitalization of $429.62 million, a PE ratio of -4.63 and a beta of 1.12.
In related news, COO Kenneth Hoberman sold 2,995 shares of the firm’s stock in a transaction that occurred on Thursday, March 7th. The stock was sold at an average price of $11.36, for a total transaction of $34,023.20. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, CEO Ivan Bergstein sold 6,800 shares of the firm’s stock in a transaction that occurred on Thursday, March 7th. The stock was sold at an average price of $11.41, for a total value of $77,588.00. The disclosure for this sale can be found here. Insiders have sold a total of 100,880 shares of company stock worth $1,145,287 in the last 90 days. 14.80% of the stock is currently owned by company insiders.
A number of large investors have recently added to or reduced their stakes in STML. Great West Life Assurance Co. Can purchased a new position in Stemline Therapeutics during the 4th quarter worth approximately $47,000. Legal & General Group Plc grew its stake in Stemline Therapeutics by 27.1% during the 4th quarter. Legal & General Group Plc now owns 5,249 shares of the biopharmaceutical company’s stock worth $50,000 after buying an additional 1,120 shares during the last quarter. Metropolitan Life Insurance Co. NY grew its stake in Stemline Therapeutics by 327.0% during the 4th quarter. Metropolitan Life Insurance Co. NY now owns 8,523 shares of the biopharmaceutical company’s stock worth $81,000 after buying an additional 6,527 shares during the last quarter. Bank of America Corp DE grew its stake in Stemline Therapeutics by 56.8% during the 4th quarter. Bank of America Corp DE now owns 10,669 shares of the biopharmaceutical company’s stock worth $101,000 after buying an additional 3,866 shares during the last quarter. Finally, Janney Montgomery Scott LLC purchased a new position in Stemline Therapeutics during the 4th quarter worth approximately $108,000. Hedge funds and other institutional investors own 64.82% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: “Stemline Therapeutics (STML) Sees Unusually-High Trading Volume” was first posted by Zolmax and is the property of of Zolmax. If you are viewing this piece of content on another domain, it was stolen and reposted in violation of U.S. & international copyright & trademark law. The original version of this piece of content can be accessed at https://zolmax.com/investing/stemline-therapeutics-stml-sees-unusually-high-trading-volume/2966140.html.
Stemline Therapeutics Company Profile (NASDAQ:STML)
Stemline Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, acquisition, development, and commercialization of proprietary oncology therapeutics in the United States and internationally. The company develops SL-401, a targeted therapy directed to the interleukin-3 receptor (IL-3R), which has completed Phase II clinical trial for patients with blastic plasmacytoid dendritic cell neoplasm; is in Phase I/II clinical trials for patients with myeloproliferative neoplasms, chronic myelomonocytic leukemia, myelofibrosis, and acute myeloid leukemia; and is in Phase I clinical trial in combination with other agents for patients with relapsed/refractory multiple myeloma.
Read More: Can systematic risk be avoided?
Receive News & Ratings for Stemline Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stemline Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.